In stable CAD, higher H-FABP also identifies individuals at higher risk for CV events and CV mortality, predicting a twofold increase in composite cardiovascular events and mortality over 24 months, independent of other clinical variables [32]. This evidence concerns the gene FABP3 and coronary artery disorder.